Tirzepatide cardiovascular safety — looking for input

nancy_portland said:

KristenIndy said: ...cardiovascular risk is just another fad...

Second this. I had assumed I was the exception until I read this.

nancy_portland said:

KristenIndy said: ...cardiovascular risk is just another fad...

Coming at nancy_portland’s question from a different direction. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.

nancy_portland said:

KristenIndy said: ...cardiovascular risk is just another fad...

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

A narrower follow-up, since the general answer is now clear:

Was that from a primary source or from a summary of one?

BiostatsBrad said:

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.6 lbs/week average
Fasting glucose (finger stick): stable at 87 mg/dL
Blood pressure (home): 116/73 average
Resting heart rate: 67 bpm (down from 83)
Waist circumference: down 17 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.